Efficacy and Safety of Dupilumab in Eosinophilic Esophagitis: A Systematic Review and Meta-Analysis
International Archives of Allergy and Immunology · 15.07.2026 · 1-7
DOI: 10.1159/000553602 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift International Archives of Allergy and Immunology, online erschienen am 15.07.2026. Verfasst von Roy Khalaf und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, McGill University, Montreal, Québec, Canada, roy.khalaf@mail.mcgill.ca. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Eosinophilic esophagitis (EoE) is a chronic, immune-mediated disorder of the esophagus driven by type-2 inflammation. Dupilumab, a monoclonal antibody targeting the IL-4Ra subunit shared by the IL-4 and IL-13 receptor complexes, has recently emerged as a targeted biologic therapy for EoE. This systematic review evaluates the evidence for dupilumab in EoE across pediatric and adult populations, focusing on efficacy, safety, and symptom improvement.
Methods
MEDLINE and Embase were searched from inception to June 30, 2025. Eligible studies included randomized controlled trials (RCTs), cohort studies, case-control studies, and case reports reporting dupilumab use in confirmed EoE. Study screening and quality assessment were performed in duplicate. Data on demographics, atopic comorbidities, dosing regimens, histologic outcomes, symptom improvement, and adverse events were extracted and summarized descriptively.
Results
Nineteen studies (three randomized trials, nine cohorts, seven case reports) comprising 760 patients were included. Dupilumab was most commonly initiated following inadequate response or intolerance to proton pump inhibitors, swallowed corticosteroids, or dietary therapy. Across RCTs, histologic remission (≤15 eos/hpf) occurred in 60%–84% of dupilumab-treated patients versus
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, McGill University, Montreal, Québec, Canada, roy.khalaf@mail.mcgill.ca.
- Department of Medicine, McGill University, Montreal, Québec, Canada.
- Department of Medicine, Division of Clinical Immunology and Allergy, McGill University Health Centre, Montreal, Québec, Canada.
- Department of Medicine, Division of Gastroenterology, McGill University, Montreal, Québec, Canada.
- Department of Pediatrics, Division of Gastroenterology, Montreal Children's Hospital, Montreal, Québec, Canada.
- Department of Pediatrics, Division of Allergy and Clinical Immunology and Dermatology, Montreal Children's Hospital, Montreal, Québec, Canada.
Zitieren
APA
Khalaf, R., Ton That, A., Tardio, N., Afif, W., Schneider, R., & Ben-Shoshan, M. (2026). Efficacy and Safety of Dupilumab in Eosinophilic Esophagitis: A Systematic Review and Meta-Analysis. International Archives of Allergy and Immunology, 1-7. https://doi.org/10.1159/000553602
Vancouver
Khalaf R, Ton That A, Tardio N, Afif W, Schneider R, Ben-Shoshan M. Efficacy and Safety of Dupilumab in Eosinophilic Esophagitis: A Systematic Review and Meta-Analysis. International Archives of Allergy and Immunology. 2026:1-7. doi:10.1159/000553602
BibTeX
@article{Khalaf2026,
author = {Khalaf, Roy and Ton That, Alexandre and Tardio, Natacha and Afif, Waqqas and Schneider, Rilla and Ben-Shoshan, Moshe},
title = {Efficacy and Safety of Dupilumab in Eosinophilic Esophagitis: A Systematic Review and Meta-Analysis},
journal = {International Archives of Allergy and Immunology},
year = {2026},
pages = {1--7},
doi = {10.1159/000553602}
}
EUVIMED